.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Covington
Federal Trade Commission
McKesson
Fish and Richardson
Boehringer Ingelheim
Farmers Insurance
Cerilliant
Moodys
Medtronic

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021743

« Back to Dashboard
NDA 021743 describes TARCEVA, which is a drug marketed by Osi Pharms and is included in one NDA. It is available from three suppliers. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the TARCEVA profile page.

The generic ingredient in TARCEVA is erlotinib hydrochloride. There are twenty-three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the erlotinib hydrochloride profile page.

Summary for NDA: 021743

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antineoplastics
Formulation / Manufacturing:see details

Pharmacology for NDA: 021743

Mechanism of ActionProtein Kinase Inhibitors

Suppliers and Packaging for NDA: 021743

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TARCEVA
erlotinib hydrochloride
TABLET;ORAL 021743 NDA Genentech, Inc. 50242-062 50242-062-01 30 TABLET in 1 BOTTLE (50242-062-01)
TARCEVA
erlotinib hydrochloride
TABLET;ORAL 021743 NDA Genentech, Inc. 50242-063 50242-063-01 30 TABLET in 1 BOTTLE (50242-063-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 25MG BASE
Approval Date:Nov 18, 2004TE:RLD:Yes
Regulatory Exclusivity Expiration:Jun 1, 2019
Regulatory Exclusivity Use:
Regulatory Exclusivity Expiration:Oct 18, 2019
Regulatory Exclusivity Use:
Patent:5,747,498*PEDPatent Expiration:May 8, 2019Product Flag?Substance Flag?Delist Request?Y


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Covington
Merck
Queensland Health
Johnson and Johnson
Deloitte
Moodys
US Department of Justice
Colorcon
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot